Blood-based wound healing tech scoops $26m investment
Summary
According to the Tel Aviv, Israel-based company, the graft is more effective than other methods and has low rates of rejection. In January 2023, the company revealed promising data showing the graft is a viable option for complex wounds.ActiGraft is currently distributing in over 30 countries. Alon Kushnir, RedDress CEO, told the network has donated 400 ActiGraft kits to Ukraine to aid wounded soldiers.Wound treatment is a main area of spending within healthcare. According to the NHS, the UK health service spends $5.3bn annually on managing wounds and their associated comorbidities. The company is investigating growing tissue over exposed bone and, after a completed trial in Israel provided promising data, has ongoing clinical trials in the US for treating anal fistula in Crohns patients and inflammatory bowel disease patients.Additionally, we are also working on supporting nerve healing, creating nerve cells in-vivo wherever it is needed, and we will be publishing results from pre-clinical trials soon, said Kushnir.Regenerative medicine is the future of the human healing process, and we are excited by what we are finding in our research and development.